This trial is to see if LY3209590 is a safe and effective treatment for Type 2 diabetes in patients who are already taking basal insulin. The study will last up to 86 weeks and will involve a 3-week screening period, a 78-week treatment period, and a 5-week safety follow-up period.
1 Primary · 10 Secondary · Reporting Duration: Week 22 to Week 26
Active Control
Experimental Treatment
1228 Total Participants · 2 Treatment Groups
Primary Treatment: LY3209590 · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
18 - 65 | 100.0% |
Gadolin Research | 50.0% |
Juno Research | 50.0% |
Did not meet criteria | 100.0% |
0 | 100.0% |